Polatuzumab combo for B-cell lymphoma

Polatuzumab vedotin in combination with bendamustine plus rituximab (BR) has been granted priority review by the US FDA for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

The GO29365, a global, phase Ib/II randomized study, showed that polatuzumab vedotin plus BR improved median overall survival compared to BR alone in people with R/R DLBCL not eligible for a hematopoietic stem cell transplant. The study also showed that 40 percent of people treated with polatuzumab vedotin plus BR achieved a complete response (CR), while only 18 percent of people treated with BR alone achieved a CR.

Polatuzumab is developed by Genentech, a member of the Roche Group.